Drug Profile
Research programme: cochleate based therapeutics - Matinas Biopharma
Alternative Names: Encochleated ibuprofen - Matinas BioPharma; Encochleated influenza vaccine - Matinas BioPharma; Encochleated siRNA; RNAi therapeuticsLatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Aquarius Biotechnologies
- Developer Aquarius Biotechnologies; Matinas BioPharma; Rutgers
- Class Catechols; Nonsteroidal anti-inflammatories; Omega 3 fatty acids; Phenylpropionates; Small interfering RNA; Small molecules; Vaccines
- Mechanism of Action Cyclooxygenase inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammation; Influenza virus infections; Unspecified; Viral infections
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Viral-infections in USA (IM)
- 28 May 2021 No recent reports of development identified for preclinical development in Viral-infections in USA (PO)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (Intranasal)